2024 AANEM annual meeting will feature NMD Pharma's Phase 2b trial of NMD670 for rare neuromuscular diseases.
NMD Pharma A/S will showcase its skeletal muscle therapy for rare neuromuscular diseases at the 2024 AANEM annual meeting. The presentation will feature preclinical and clinical data, focusing on its Phase 2b trial of NMD670, an oral small molecule inhibitor targeting the ClC-1 chloride channel. This double-blind, placebo-controlled study began in June 2024, assessing its effects on generalized myasthenia gravis patients. Participation is encouraged for eligible patients in the US and Europe.
October 11, 2024
3 Articles